Enrollment Closed
Interventional

The Phoenix Trial

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - (PHOENIX)

Brief Description

*Enrollment is now closed. We will keep you updated on the results of this study as they are published.
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in patients with rare forms of chronic kidney disease.

Study Coordinator

Syed N Babar

Email Phone (706)722-6900
Site Name

Kidney Care Augusta

Sponsor

Reata Pharmaceuticals, Inc.

Study Drug

Bardoxolone

Estimated enrollment

100

Estimated end date

July, 2019

If there is not a site for a clinical trial nearby, you can ask the study team about the possibility of travel reimbursements (i.e., paying you back for your travel costs). Alternatively, you can ask about the possibility of participating from home.
Enrollment Closed
Interventional

The Phoenix Trial

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - (PHOENIX)

Brief Description

*Enrollment is now closed. We will keep you updated on the results of this study as they are published.
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in patients with rare forms of chronic kidney disease.

Trial for people with

Primary Membranous Nephropathy (MN), IgA Nephropathy (IgAN), C3 Glomerulopathy (C3G)

Study Goal

Patients will be enrolled in disease specific cohorts within the trial, and effectiveness of bardoxolone methyl in treating kidney disease will be assessed separately by cohort for each rare CKD.

What is involved for the Patient?

Participation in PHOENIX may last up to 16 weeks, and will include 10 study visits and 6 scheduled phone calls.

About the drug or intervention

Bardoxolone Methyl is an oral medication that inhibits an inflammatory pathway in the body.

Augusta, GA
Frequently Asked Questions

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

The Kidney Health Gateway is a website owned and operated by NephCure Kidney International. The purpose of this website is to help patients with rare forms of primary Nephrotic Syndrome get connected to expert care and cutting-edge treatment options. By answering a few questions about you or your loved one’s condition, we can provide you with a list of clinical trials and/or expert doctors in your area.

If you have additional questions, please visit NephCure.org or email Info@NephCure.org.

 

See other frequently asked questions